フォローフィードコミュニティでトレーダーや投資家とつながりましょう.
包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.
ターミナル モニターで株式と資産のウォッチリストを整理および監視します
GAITHERSBURG, Md., Dec. 28 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it intends to develop a monoclonal...
GAITHERSBURG, Md., Dec. 20 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it has licensed its proprietary reverse...
- Initial Focus on Monoclonal Antibody Targeting IL-5 Receptor in Phase 1 Trials with Asthma Patients - GAITHERSBURG, Md., and PRINCETON, N.J...
GAITHERSBURG, Md., Dec. 18 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced that it has completed its sale of CytoGam(R...
Households with Children in Vaccine-Program Schools Report Fewer Doctor's Office Visits, Less Absenteeism from School and Work GAITHERSBURG, Md...
ORLANDO, Fla., Dec. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that results from three programs within the...
GAITHERSBURG, Md., Dec. 6 /PRNewswire-FirstCall/ -- Highlighting its proven strengths in discovering, developing and commercializing multiple...
- Appointments Strengthen Development Management Team and Augment Medical Affairs Expertise - GAITHERSBURG, Md., Dec. 5 /PRNewswire-FirstCall/...
GAITHERSBURG, Md., Dec. 1 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that the Washington Business Journal has named...
GAITHERSBURG, Md., Nov. 21 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) announced today that it will present at the Lazard Capital...
- Biotechnology Company Creates New Government Project Management Post - GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/ -- MedImmune, Inc...
Company Reaches Key Milestone in Commitment to HHS and National Pandemic Preparedness GAITHERSBURG, Md., Nov. 9 /PRNewswire-FirstCall/...
GAITHERSBURG, Md., Nov. 8 /PRNewswire-FirstCall/ -- MedImmune, Inc. (NASDAQ:MEDI) today announced its intent to sell CytoGam(R) (cytomegalovirus...
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約